Who is on it, and how far along Every drug ChEMBL records acting on PARP1, by the furthest stage it has reached for any use, coloured by modality.
How to read this Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
Approved2 Olaparib Olaparib SponsorAstraZeneca Pharmaceuticals ModalitySmall molecule ActionInhibitor Open trials229 Rucaparib Rucaparib SponsorBristol-Myers Squibb ModalitySmall molecule ActionInhibitor Open trials12 Phase 31 Veliparib Veliparib SponsorAbbVie ModalitySmall molecule ActionInhibitor Open trials13 Phase 21 E-7016 E-7016 SponsorEisai ModalitySmall molecule ActionInhibitor Open trials0
Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: PARP 1, 2 and 3 inhibitor. The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 24 in all, from ClinicalTrials.gov. Trial Drug Phase Status Lead sponsor First posted PARP Inhibition for Biliary Tract Cancer With Mutations in Core and Non-Core Homologous Recombination Deficiency Genes Olaparib Phase 2 Not yet recruiting Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest Nov 16, 2026 Phase Ib/II Clinical Study of QLS5133 Combination Therapy in Advanced Solid Tumors Olaparib Phase 1 / Phase 2 Not yet recruiting Qilu Pharmaceutical Co., Ltd. Nov 12, 2026 Phase 1/2 Study Of PARP Inhibition With Olaparib To Enhance The Efficacy Of High-Dose Chemotherapy In Refractory And Relapsed Germ Cell Tumors Olaparib Phase 1 / Phase 2 Not yet recruiting M.D. Anderson Cancer Center Oct 1, 2026 Molecularly Tailored Therapy in Advanced Pancreatic Cancer Olaparib Phase 2 Not yet recruiting Herlev Hospital Sep 3, 2026 Olaparib+Trastuzumab+Pertuzumab Neoadjuvant for Elderly HER2+ Breast Cancer Olaparib Phase 4 Recruiting Wen-Ming Cao Jul 10, 2026 PROLONG (PRostateOLaparibONcombinationGcc) Study Olaparib — Not yet recruiting AstraZeneca Jun 29, 2026 Rucaparib Monoclonal Antibody for Lorlatinib-Induced Hypercholesterolemia / Mixed Rucaparib Phase 4 Not yet recruiting Hunan Cancer Hospital Jun 29, 2026 An Exploratory Study on the Use of Ipalotinib (Tislelizumab) Combined With Sunitinib and Olaparib for Neoadjuvant Therapy in HRD-positive Advanced Ovarian Cancer Olaparib Phase 2 Recruiting Bai-Rong Xia Jun 25, 2026 Phase 1 Study of a Self-amplifying RNA Vaccine (ITI-5000) in Stage 2-3 Triple Negative Breast Cancer Olaparib Phase 1 Recruiting Immunomic Therapeutics, Inc. Jun 17, 2026 Telmisartan in Prostate Cancer Rucaparib Phase 1 Recruiting Tyler J Curiel Dec 13, 2023 Microdevice In Ovarian, Fallopian Tube, And Peritoneal Cancer Rucaparib Phase 1 Recruiting Brigham and Women's Hospital Jan 8, 2021 A Study of Rucaparib and Nivolumab in People With Leiomyosarcoma Rucaparib Phase 2 Active, not recruiting Memorial Sloan Kettering Cancer Center Nov 10, 2020 A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy Rucaparib Phase 3 Active, not recruiting Alliance for Clinical Trials in Oncology Jul 2, 2020 A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer Rucaparib Phase 1 / Phase 2 Active, not recruiting Brown University Feb 5, 2020 Pan Tumor Rollover Study Rucaparib Phase 2 Recruiting Bristol-Myers Squibb Apr 2, 2019 A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study Rucaparib Phase 3 Active, not recruiting Hoffmann-La Roche Dec 7, 2018 Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations Veliparib Phase 2 Active, not recruiting Children's Oncology Group Jul 10, 2018 Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia Veliparib Phase 2 Active, not recruiting National Cancer Institute (NCI) Sep 21, 2017 Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Veliparib Phase 2 / Phase 3 Active, not recruiting National Cancer Institute (NCI) Jun 2, 2014 Temozolomide With or Without Veliparib in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer Veliparib Phase 2 Active, not recruiting National Cancer Institute (NCI) Jul 11, 2012 Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer Veliparib Phase 2 Active, not recruiting National Cancer Institute (NCI) Apr 26, 2012 Veliparib and Dinaciclib in Treating Patients With Advanced Solid Tumors Veliparib Phase 1 Active, not recruiting National Cancer Institute (NCI) Sep 14, 2011 Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery Veliparib Phase 1 / Phase 2 Active, not recruiting National Cancer Institute (NCI) Jul 1, 2011 Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction Veliparib Phase 1 Active, not recruiting National Cancer Institute (NCI) Jun 3, 2011
Show all 24Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3390820 , ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov , checked daily; this page as of 2026-11-21. ChEMBL and Open Targets